Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01251978 · ClinicalTrials.gov registry record · Phase 2
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
A Phase 2 study of Choroidal Melanoma, sponsored by New England Retina Associates.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT01251978 is a Phase 2 study of Choroidal Melanoma that has completed, run by New England Retina Associates. The registered enrollment target is 10 participants, below the 213-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01251978, a Phase 2 study of Choroidal Melanoma, has completed, sponsored by New England Retina Associates.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
Conditions Studied
Interventions
- DRUG Ranibizumab 2 mg
- DRUG 0.5 mg Ranibizumab
Study Locations (1)
Connecticut
- New England Retina Associates - Hamden
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2010-07 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01251978
The ClinicalTrials.gov registry entry for NCT01251978 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 213-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (95% lower). The listed sponsor is New England Retina Associates, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choroidal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Ranibizumab 2 mg is the first listed.
NCT01251978 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT01251978 about?
NCT01251978 is a clinical study titled "Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)". Ranibizumab has proven to be of benefit to improve the perfusion in the retina of patients with Choroidal Melanoma. The investigators consider that higher doses of Ranibizumab can help reduce the number of laser treatments that might be needed to control the tumor.
What is the current status of trial NCT01251978?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2010-07. Estimated completion is 2012-08.
What conditions does trial NCT01251978 study?
This clinical trial studies the following conditions: Choroidal Melanoma.
What interventions are being tested in trial NCT01251978?
The interventions under investigation include: Ranibizumab 2 mg (DRUG), 0.5 mg Ranibizumab (DRUG).
Who is sponsoring clinical trial NCT01251978?
This trial is sponsored by New England Retina Associates, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01251978 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
RECRUITING
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.